Skip to main content
. 2021 Oct 8;23(Suppl E):E59–E62. doi: 10.1093/eurheartj/suab090

Figure 2.

Figure 2

Key milestones in the development of subcutaneous inclisiran for use in hypercholesterolaemia and mixed dyslipidaemia. CHMP, Committee for Medicinal Products for Human Use; HoFH, homozygous familial hypercholesterolaemia. Reproduced with permission of Springer Nature.14